Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Obesity - Body's effort to protect organs from lipids' toxic effects

Obesity - Body's effort to protect organs from lipids' toxic effects

Proper treatment can help control psoriasis in most cases

Proper treatment can help control psoriasis in most cases

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk awarded contract by VA as primary source provider of insulin

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Evolving sex disparity in midlife stroke prevalence: Further study needed

Evolving sex disparity in midlife stroke prevalence: Further study needed

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

Excessive weight gain during pregnancy linked to increased risk of gestational diabetes

Excessive weight gain during pregnancy linked to increased risk of gestational diabetes

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

StayWell Consumer Health Publishing to feature consumer health information in Pathway Genomics Genetic Health Report

StayWell Consumer Health Publishing to feature consumer health information in Pathway Genomics Genetic Health Report

Studies show association between high levels of vitamin D and decreased risk of heart disease

Studies show association between high levels of vitamin D and decreased risk of heart disease

TZD drug may increase fracture risk in older women

TZD drug may increase fracture risk in older women

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

FDA approves Novo Nordisk's Victoza for type 2 diabetes

FDA approves Novo Nordisk's Victoza for type 2 diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.